On Thursday, Vigil Neuroscience Inc. (NASDAQ:VIGL) released data from its completed Phase 1 trial evaluating VG-3927 as a potential treatment for Alzheimer’s disease. Demonstrated a favorable ...
Vigil Neuroscience plans a Phase 2 trial for Alzheimer's in Q3 2025, advancing a once-daily 25mg oral dose. The company plans to advance a once-daily oral dose of 25mg and expects to initiate the ...
Commission will be hosting a Legacy With Candlelight Vigil, Fireworks Spectacular in ... to arrive early to get a good spot to view the show, and to bring chairs or blankets to be comfortable.
Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially representing a new avenue for treating Alzheimer’s disease. In a possible ...
Every year at our Vigil of All Saints, we meet people who say: “This is great! Why don’t we do this everywhere?” In fact, every year, we get inquiries from around the country asking us to ...
Close to 100 first responders and community members gathered at the Calcutta Fire Department to support Officer Dakota Wetzel who is recovering in the hospital and his family as well as the family ...